Castleview Partners’s ProKidney PROK Stock Holding History

Castleview Partners’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,900	Closed	-$51.7K	–	458
2024 Q4	$51.7K	Sell	29,900 -3,021	-9%	-$5.45K	0.03%	336
2024 Q3	$63.2K	Buy	+32,921	New	+$74.7K	0.04%	297

Other funds holding PROK

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Castleview Partners's PROK Position: Q1 2025 in Review

Castleview Partners sold out of ProKidney (PROK) in Q1 2025, closing a stake of 29,900 shares — an estimated $51.7K sold.

Castleview Partners first reported a position in PROK in Q3 2024 and held it in 2 quarters. The position peaked at $63.2K in Q3 2024. 69 funds tracked by Wall St. Rank hold PROK as of Q1 2025.

Castleview Partners reported no remaining ProKidney position as of Q1 2025 after selling out during the quarter.
Castleview Partners sold 29,900 ProKidney shares in Q1 2025, an estimated $51.7K.
Castleview Partners first reported a position in ProKidney in Q3 2024 and held it in 2 quarters.
Castleview Partners's ProKidney position peaked at $63.2K in Q3 2024.
69 funds tracked by Wall St. Rank held ProKidney as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.